Eli Lilly Could Become The World’s Top AI Firm? Jordi Visser Has Reasons To Believe Mounjaro Maker Could
Speaking on “The Pomp Podcast” with crypto investor and entrepreneur Anthony Pompliano Saturday, Visser said Eli Lilly’s more…
Novo Nordisk Extends Lead As Eli Lilly New Obesity Pill Sees Modest Launch Uptake – Eli Lilly (NYSE:LLY)
Early Prescription Trends Show Slower Start For Lilly Reuters, citing IQVIA data, reported that Eli Lilly recorded 1,390…
Eli Lilly Just Launched Its $149 Obesity Pill – Eli Lilly (NYSE:LLY)
Eli Lilly and Co. (NYSE:LLY) on Wednesday announced that Foundayo (orforglipron) is now available to adults with obesity…
Novo Nordisk Will Soon Reveal Whether Its GLP-1 Drug Can Slow Alzheimer’s – Novo Nordisk (NYSE:NVO)
Upcoming data from Novo Nordisk A/S (NYSE:NVO) early next month could offer the clearest signal yet on whether…
AI Bubble Fear? This Sector Is Quietly Surging While Tech Sinks – Amgen (NASDAQ:AMGN), Bristol-Myers Squibb (NYSE:BMY)
It hasn’t been an easy stretch for technology and AI stocks, with triple-digit year-to-date gainers like Palantir Technologies…
Wegovy And Zepbound Cost Effective But They Could Break Drug Budgets – Novo Nordisk (NYSE:NVO), Eli Lilly (NYSE:LLY)
The Institute for Clinical and Economic Review (ICER) on Tuesday released a Draft Evidence Report assessing the comparative…
Bristol‑Myers Squibb, Pfizer Set To Launch Direct‑To‑Patient Eliquis At 40% Off – Pfizer (NYSE:PFE), Bristol-Myers Squibb (NYSE:BMY)
The Bristol Myers Squibb Co. BMY and Pfizer Inc. PFE alliance announced a new direct-to-patient option for purchasing Eliquis (apixaban) via…